SAB Biotherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
05 janv. 2022 07h00 HE
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Jan. 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
16 déc. 2021 07h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety,...
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
01 déc. 2021 07h00 HE
|
SAB Biotherapeutics, Inc.
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by...
Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart
18 nov. 2021 16h02 HE
|
Vaxart, Inc.
STANFORD, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- A new Stanford study published in Cell Host and Microbe has demonstrated that VXA-A1.1, an investigational oral tablet flu vaccine under...
Lateral Flow Assays Market revenue to cross USD 11.7 Bn by 2027: Global Market Insights Inc.
03 nov. 2021 06h30 HE
|
Global Market Insights, Inc
Selbyville, Delaware, Nov. 03, 2021 (GLOBE NEWSWIRE) -- The lateral flow assays market size is anticipated to record a valuation of USD 11.7 billion by 2027, according to the most recent study by...
7 Hills Pharma Announces the Completion of a Landmark Phase I Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines
01 nov. 2021 15h08 HE
|
7 Hills Pharma
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage drug development company bringing to market a platform of unique, first-in-concept oral small...
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021
21 oct. 2021 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter...
Vir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference
30 sept. 2021 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., chief medical officer, is scheduled to present at the Guggenheim...
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
22 juin 2021 01h00 HE
|
Translate Bio, Inc.
-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data...
Enochian BioSciences Announces Acquisition of Exclusive License for Potential Pan-Coronavirus and Pan-Influenza Inhaled Treatment and Prevention Technology
21 juin 2021 07h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, June 21, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...